(S)-2-Ethoxy-butane-1,4-diol | 869891-19-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-2-Ethoxy-butane-1,4-diol
• 英文别名: (2S)-2-ethoxybutane-1,4-diol
• CAS: 869891-19-0
• 化学式: C₆H₁₄O₃
• 分子量: 134.175
• InChiKey: IRZLMNRFLJUTJZ-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-Ethoxy-butane-1,4-diol 在 palladium on activated charcoal 吡啶 、 sodium azide 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 100.0 ℃ 、7.3 MPa 条件下， 反应 9.5h， 生成 (S)-2-ethoxy-1,4-diaminobutane
  参考文献：
  名称：

  Synthesis and in vitro cytotoxicity of novel hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes

  摘要：

  Twenty-six new hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes having a seven-membered ring structure between a bidentate carrier ligand and a platinum atom have been synthesized and most of them were evaluated for their in vitro cytotoxicity toward A549 human non-small cell lung carcinoma and HCT-116 human colon cancer cell lines. The cytotoxicities of platinum complexes are related to the nature of the carrier ligand and leaving group. Complex 5'b, viz. cis-dichloro[(2R)ethoxy-1,4-butanediamine] platinum (11), exhibits the greatest potency among those 21 tested platinum complexes in both cell lines. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.025
• 作为产物：
  描述：

  ethyl ether l-malic acid diethyl ester 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (S)-2-Ethoxy-butane-1,4-diol
  参考文献：
  名称：

  Synthesis and in vitro cytotoxicity of novel hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes

  摘要：

  Twenty-six new hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes having a seven-membered ring structure between a bidentate carrier ligand and a platinum atom have been synthesized and most of them were evaluated for their in vitro cytotoxicity toward A549 human non-small cell lung carcinoma and HCT-116 human colon cancer cell lines. The cytotoxicities of platinum complexes are related to the nature of the carrier ligand and leaving group. Complex 5'b, viz. cis-dichloro[(2R)ethoxy-1,4-butanediamine] platinum (11), exhibits the greatest potency among those 21 tested platinum complexes in both cell lines. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.025

文献信息

• 1-( -D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1803729A1

  公开（公告）日：2007-07-04

  A compound having SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-(β-D-glycopyranosyl)-3-substituted nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a medicinal use thereof. In the formula, ring A represents optionally substituted aryl or heteroaryl; Q1 to Q5 independently represent a carbon atom having a hydrogen atom or substituent bonded thereto or a nitrogen atom; E represents a single bond, alkylene, -O-, -S- or -NH-; and R.represents methyl, ethyl, fluoromethyl or hydroxymethyl.

  一种具有 SGLT1 和/或 SGLT2 抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖症、糖耐量受损、糖尿病并发症、肥胖症等的药物。它是由通式（I）代表的1-（β-D-吡喃甘露糖基）-3-取代的含氮杂环化合物、其原药或药学上可接受的盐，或其水合物或溶液；含有相同物质的SGLT抑制剂；含有相同物质的药物组合物及其药用用途。式中，环A代表任选取代的芳基或杂芳基；Q1至Q5独立地代表具有氢原子或取代基键合的碳原子或氮原子；E代表单键、亚烷基、-O-、-S-或-NH-；R.代表甲基、乙基、氟甲基或羟甲基。